Replimune to Resubmit RP1 BLA for Advanced Melanoma After FDA Agreement
Summary
Replimune Group announced an agreement with the FDA to resubmit its Biologics License Application for RP1 in advanced melanoma, with the FDA committing to an urgent and prioritized review.
Key Events
-
FDA Agreement for RP1 Resubmission
Replimune has reached an agreement with the U.S. Food and Drug Administration (FDA) to resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for advanced melanoma.
-
Prioritized Review by FDA
The FDA has indicated it will treat the BLA resubmission as an urgent matter and will prioritize its review, acknowledging the significant unmet need for patients with advanced melanoma.
-
Reversal of Previous Setback
This development provides a path forward for RP1 after the FDA previously issued a Complete Response Letter in April 2026, which led to job cuts and a significant stock price decline.
Analysis
This 8-K announces a critical positive development for Replimune's lead product candidate, RP1. Following a previous Complete Response Letter from the FDA in April 2026, the company has now reached an agreement with the agency to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma. The FDA has committed to an urgent and prioritized review, which significantly de-risks the regulatory path for RP1 and provides a potential path to market for a drug previously facing rejection. This news directly addresses a major setback that caused a significant stock price decline.
At the time of this filing, REPL was trading at $8.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $675.9M. The 52-week trading range was $1.50 to $13.24. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.